86983-92-8

Upstream product

• 563-80-4 3-methyl-butan-2-one 
• 555-16-8 4-nitrobenzaldehdye 
• 261527-27-9 1-acetoxy-4-methyl-1-(p-nitrophenyl)pentan-3-one 
• 261527-26-8 1-hydroxy-4-methyl-1-(4-nitrophenyl)pentan-3-one 
• 19967-55-6 1-bromo-3-methyl-2-butanone 
• 121077-68-7 (3-methyl-2-oxobutyl)triphenyl-arsonium bromide 

Downstream Products

• 207737-47-1 1-(4-Amino-phenyl)-4-methyl-pentan-3-one 
• 261527-36-0 3-[2-(p-aminophenyl)-ethyl]-3-hydroxy-4-methylpentanoic acid 
• 261527-25-7 3-[2-(p-N-acetylaminophenyl)ethyl]-3-hydroxy-4-methylpentanoic acid 
• 313256-73-4 3-hydroxy-3-isopropyl-5-(p-nitrophenyl)-4-pentenoic acid benzyl ester 
• 86983-94-0 (E)-3-chloro-4-methyl-1-p-nitrophenylpent-1-ene 
• 207737-55-1 (S)-6-[2-(4-tert-butoxycarbonylaminophenyl)ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one 
• 207736-05-8 (R)-6-[2-(4-aminophenyl)ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one 
• 207736-05-8 CI-1029 
• 207737-53-9 5-[2-(4-tert-butoxycarbonylamino-phenyl)-ethyl]-5-hydroxy-6-methyl-3-oxo-heptanoic acid ethyl ester 
• 260257-69-0 3-hydroxy-3-[2-(4-tert-butoxycarbonylaminophenyl)ethyl]-4-methylpentanoic acid benzyl ester 
• 260257-72-5 (R)-6-[2-(4-(tert-butoxycarbonylamino)phenyl)ethyl]-4-hydroxy-6-isopropyl-5,6-dihydropyran-2-one 
• 207737-54-0 (S)-6-[2-(4-(tert-butoxycarbonylamino)phenyl)ethyl]-4-hydroxy-6-isopropyl-5,6-dihydropyran-2-one 
• 207737-57-3 6-[2-(4-(tert-butoxycarbonylamino)phenyl)ethyl]-4-hydroxy-6-isopropyl-5,6-dihydropyran-2-one 
• 260258-06-8 (R)-3-hydroxy-3-[2-(4-tert-butoxycarbonylaminophenyl)ethyl]-4-methylpentanoic acid 

Relevant academic research and scientific papers

Methods of making dihydropyrone HIV protease inhibitors

The present invention relates to methods of making dihydropyrone HIV inhibitors.

Application of the Sch?pf method to optimization of the synthesis of 3-[2-(p-N-acetylaminophenyl)ethyl]-3-hydroxy-4-methylpentanoic acid: Simultaneous reduction of three functional groups to maximize yield and throughput

Application of the Sch?pf method to development of a high yield condensation process to prepare a labile β-(p-nitrophenyl)-α,β-unsaturated ketone system, along with development of a procedure for simultaneous hydrogenation/hydrogenolysis of olefin, benzyl

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: A lead HIV protease inhibitor

With the insight generated by the availability of X-ray crystal structures of various 5,6-dihydropyran-2-ones bound to HIV PR, inhibitors possessing various alkyl groups at the 6-position of 5,6-dihydropyran-2-one ring were synthesized. The inhibitors pos

Radical and Ionic Nucleophilic Substitution Reactions on α-Alkyl-γ-(p-nitrophenyl)allyl Derivatives

The nature of the reaction between α-alkyl-γ-(p-nitrophenyl)allyl chlorides (1)-(3), which have the general form p-O2NC6H4CH=CHCH(Cl)R, and a variety of nucleophiles depends on the alkyl group R and the nucleophile.The chloride (1) (R = Me) undergoes ionic (SN2 and subsequent Michael addition) processes with the salt (7) of 2-nitropropane to give products (15) and (16) whereas the chloride (2) (R = Pri) gives a mixture of products (17) and (18) which are shown to arise by a radical-chain nucleophilic substitution process, with allylic rearrangement-an SRN1' reaction- and ionic processes respectively.The chloride (3) (R = But) gives the SRN1' product (25) with the salt (7).Other nucleophiles with (2) and (3) appear to react by ionic (SN2 and SN2') and/or SRN1' processes; e.g. (3) gives an excellent yield of the malononitrile (32) by an SN2' process when treated with the sodium salt (9).